NO20055923L - Farmasoytisk anvendbare salter av karboksylsyrderivater - Google Patents

Farmasoytisk anvendbare salter av karboksylsyrderivater

Info

Publication number
NO20055923L
NO20055923L NO20055923A NO20055923A NO20055923L NO 20055923 L NO20055923 L NO 20055923L NO 20055923 A NO20055923 A NO 20055923A NO 20055923 A NO20055923 A NO 20055923A NO 20055923 L NO20055923 L NO 20055923L
Authority
NO
Norway
Prior art keywords
carboxylic acid
acid derivatives
pharmaceutically usable
usable salts
salts
Prior art date
Application number
NO20055923A
Other languages
English (en)
Inventor
Erica Stahle
Ralf Ragnar
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20055923L publication Critical patent/NO20055923L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Et kalsium- eller magnesiumsalt av (2S)-2-etoksy-3-(4-{2-[heksyl(2-fenyletyl)amino]-2- oksoetoksy } fenyl)propansyre.
NO20055923A 2003-06-18 2005-12-13 Farmasoytisk anvendbare salter av karboksylsyrderivater NO20055923L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0314136.3A GB0314136D0 (en) 2003-06-18 2003-06-18 Therapeutic agents
PCT/SE2004/000965 WO2004110985A1 (en) 2003-06-18 2004-06-16 Pharmaceutically useful salts of carboxylic acid derivates

Publications (1)

Publication Number Publication Date
NO20055923L true NO20055923L (no) 2006-01-06

Family

ID=27636795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055923A NO20055923L (no) 2003-06-18 2005-12-13 Farmasoytisk anvendbare salter av karboksylsyrderivater

Country Status (21)

Country Link
US (1) US20060194879A1 (no)
EP (1) EP1638921A1 (no)
JP (1) JP3836498B1 (no)
KR (1) KR20060017646A (no)
CN (1) CN1805922A (no)
AR (1) AR044802A1 (no)
AU (1) AU2004247611A1 (no)
BR (1) BRPI0411455A (no)
CA (1) CA2527608A1 (no)
CO (1) CO5650229A2 (no)
GB (1) GB0314136D0 (no)
IL (1) IL172168A0 (no)
IS (1) IS8232A (no)
MX (1) MXPA05013713A (no)
NO (1) NO20055923L (no)
RU (1) RU2005138369A (no)
SA (1) SA04250170B1 (no)
TW (1) TW200503678A (no)
UY (1) UY28371A1 (no)
WO (1) WO2004110985A1 (no)
ZA (1) ZA200510199B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
DK1517883T3 (da) 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
PE20081463A1 (es) * 2006-10-20 2008-10-18 Janssen Pharmaceutica Nv Formas salinas de compuestos de benzotienilo sustituido

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200102908T2 (tr) * 1999-04-06 2002-04-22 Sankyo Company Limited alfa-İkameli karboksilik asit türevleri
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
US20060194879A1 (en) 2006-08-31
BRPI0411455A (pt) 2006-07-18
MXPA05013713A (es) 2006-06-27
JP3836498B1 (ja) 2006-10-25
ZA200510199B (en) 2006-12-27
RU2005138369A (ru) 2007-07-27
GB0314136D0 (en) 2003-07-23
CA2527608A1 (en) 2004-12-23
IS8232A (is) 2006-01-13
WO2004110985A1 (en) 2004-12-23
UY28371A1 (es) 2005-01-31
CN1805922A (zh) 2006-07-19
KR20060017646A (ko) 2006-02-24
SA04250170B1 (ar) 2007-10-29
EP1638921A1 (en) 2006-03-29
IL172168A0 (en) 2009-02-11
AR044802A1 (es) 2005-10-05
AU2004247611A1 (en) 2004-12-23
JP2006527767A (ja) 2006-12-07
CO5650229A2 (es) 2006-06-30
TW200503678A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
NO20055923L (no) Farmasoytisk anvendbare salter av karboksylsyrderivater
NO20055922L (no) Farmasoytiske anvendbare salter av karboksylsyrderivater
CR8218A (es) Antidoto sobre la base de derivados de acidos carboxilicos aromaticos alifaticos
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
MA29416B1 (fr) Inhibiteurs d'age
DE602004024545D1 (de) Indungen
MY148953A (en) Substituted biphenyl carboxylic acids and derivatives thereof
NO20073755L (no) Ibandronatpolymorf B
JP2008510815A5 (ja) プラスミノゲン活性化因子阻害剤１型（ｐａｉ−１）調節剤としてのオキサゾロ−ナフチル酸
PL362366A1 (en) New method of industrial synthesis of tetra esters of 5-[bis(carboxyl methyl)amino]-3 -karboxymethyl-4-cyano-2-tio phenokarboxylic acid, method of manufacture of divalent salts of ranelic acid and their hydrates, as well as new intermediate compounds
EA200900707A1 (ru) Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
RS52108B (en) 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS
CY1111881T1 (el) Υδατικη φαρμακοτεχνικη μορφη του 4-[((4-καρβοξυβουτυλο)-{2-[(4-φαιναιθυλο-βενζυλο)οξυ]φαιναιθυλο}-αμινο)μεθυλο]βενζοϊκου οξεος
DE502006009412D1 (de) Matrixkontrolliertes transdermales system mit salzen der ace-hemmer-dicarbonsäuren
DE60326720D1 (de) Sulfonsäuresalze von Mandelsäurederivaten
SE0403072D0 (sv) Pharmaceutically useful salts of carboxylic acid derivates
EA200701925A1 (ru) Способ получения энантиомерночистых e-2(s)-алкил-5-галопент-4-еновых кислот и их сложных эфиров
ITMI20042231A1 (it) Cefdinir sale d'ammonio in forma cristallina
TH81758A (th) เกลือของอนุพันธ์คาร์บอกซิลิคแอซิดที่มีประโยชน์ในทางเภสัชกรรม
NO20091308L (no) Framgangsmate
TH69770A (th) สารรักษาโรค
FI20021510A (fi) Karboksyylihapon suolojen valmistusprosessi
ITMI20031326A0 (it) Sali di acidi idrossicinnamici e di idrossistilbeni otticamente attivi
AR053121A1 (es) Derivados racemicos y opticamente activos del acido 4-cloro-3-(5-cloro-3-alquil-2-oxo-2,3-dihidro-1h-indol-3-il)benzoico
CU20080249A7 (es) Formulación farmacológica acuosa de ácido 4-[((4-carboxibutil)-{2-[(4-fenetil-bencil)oxi]-fenetil}amino)metil]benzoico

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application